Prostate Cancer

Neoadjuvant chemohormonal therapy warrants consideration in the management of men undergoing radical prostatectomy for clinically localized high-risk prostate cancer, said James Eastham, MD, at the American Society of Clinical Oncology annual meeting in Chicago.

Results of a phase III trial show the benefit of darolutamide (Nubeqa) in reducing the risk of metastases or death compared with placebo in men with nonmetastatic castration-resistant prostate cancer.

Race does not affect oncologic response to treatment with docetaxel (Taxotere)/prednisone in men with metastatic castrate-resistant prostate cancer, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.

18F-DCFPyL PET/CT imaging demonstrated excellent performance in identifying regional or distant metastases in men with prostate cancer in the prospective OSPREY study.

A pivotal phase II trial of a novel MRI-guided ultrasound ablation treatment exceeded its primary efficacy endpoint of PSA decline in men with organ-confined prostate cancer.

These six questions are meant to test your knowledge of the updates to the AUA's treatment guideline for castration-resistant prostate cancer.

"This report brings to light an often-suspected but previously undocumented clinical issue in great and alarming detail," says Badar M. Mian, MD.

Data from a recent study suggest that exposure to dust from the World Trade Center attack has resulted in an inflammatory cascade that led to the development of high-grade prostate cancer in first responders.

“This study supports an association between body fat distribution and prostate cancer risk,” says researcher Barbra Dickerman, PhD.

A significant proportion of men who progress radiologically while on the androgen receptor inhibitor enzalutamide (XTANDI) do not meet standard criteria for PSA progression, reported Fred Saad, MD.

"Deciding what care is appropriate is already extraordinarily difficult but will be a growing problem for the next generation of physicians and society," writes Peter C. Albertsen, MD.

Integration of tumor genetic testing and genomically-informed therapies into clinical practice for patients with advanced prostate cancer are featured in updated National Comprehensive Cancer Network guidelines on the management of prostate cancer (version 2.2019).

Men with low levels of free testosterone 3 months after undergoing radical prostatectomy could face increased chance of early recurrence of prostate cancer, according to researchers from the University of California Irvine.

More research is needed to determine the value of using magnetic resonance imaging to predict pathology outcomes following radical prostatectomy, according to a study presented at the AUA annual meeting in Chicago.

Radiation is a well-tolerated and effective salvage option following primary high-intensity focal ultrasound for the treatment of localized prostate cancer, according to findings from a single-institution retrospective analysis.

Following a program that combines a low carbohydrate diet and modest walking may be an effective strategy for blocking many of the adverse metabolic effects of androgen deprivation therapy, according to findings of a randomized controlled trial.

"In this study, even if only the higher risk subgroup (unfavorable PSMs and advanced stage/grade) were to receive adjuvant treatment, nearly 75% of patients may potentially be overtreated," writes Badar M. Mian, MD.

"Therapeutic layering... is now becoming commonplace in the initial treatment of newly diagnosed metastatic prostate cancer," writes Leonard G. Gomella, MD.

"Despite improvements in the diagnostic markers and imaging, overdiagnosis and particularly overtreatment continue to pose a challenge for the urologic community," writes Badar M. Mian, MD.

"There’s mounting evidence that the risk for dementia increases with prolonged use. While impacting only a minority of patients, I think the risk is real," says one urologist.

Researchers evaluated a retrospective cohort of 10 patients with 26 primary prostate tumors who underwent MRI prior to prostatectomy.

African-American men with metastatic castration-resistant prostate cancer who were treated with abiraterone acetate (ZYTIGA) or enzalutamide (XTANDI) and who had not received prior chemotherapy lived 20% longer over 5 years compared with their Caucasian counterparts.

Nearly 90% of men with hormone-sensitive prostate cancer (HSPC) who initiate androgen deprivation therapy (ADT) have at least one bone metabolism biomarker that is elevated. 

Inflammatory bowel disease increases the risk of any and clinically significant prostate cancer, according to an examination of data from a large, single medical network.